Malaria Author: Rick M. Fairhurst, MD, PhD; Thomas E. Wellems, MD, PhD
Module updated - 2010-01-12
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up

Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools
Non-drug Therapy
  • Maintain normal blood glucose levels in patients with severe malaria.
  • Consider exchange transfusion in some cases as an adjunct in the treatment of severe P. falciparum malaria.


Maintain normal blood glucose levels in patients with severe malaria. B

  • Check serum glucose at presentation and every 4 hours during the course of the disease, as well as with seizures or any acute change in mental status.
  • Administer 5% or 10% dextrose infusions as needed to keep serum glucose in the normal range.
Background | Back to top


Consider exchange transfusion in some cases as an adjunct in the treatment of severe P. falciparum malaria. B

  • Consider exchange transfusion in patients who meet World Health Organization guidelines for severe malaria:
    • Parasitemia >30% in the absence of clinical complications
    • Parasitemia >10% in the presence of severe disease, especially:
      • Cerebral malaria
      • Acute renal failure
      • Adult respiratory distress syndrome
      • Jaundice
      • Severe anemia
    • Parasitemia >10% and failure to respond to optimal chemotherapy after 12 to 24 hours
    • Parasitemia >10% and poor prognostic factors, such as:
      • Elderly patient
      • Late-stage parasites in peripheral blood
  • Be aware that exchange transfusion:
    • May be harmful and is associated with fluid overload, risk of transfusion reactions and related infections, and line sepsis
    • Does not remove infected erythrocytes that are sequestered in deep tissue capillary beds, including those in the brain
    • Does not reduce the parasitemia to zero
Background | Back to top

FAQs
Harry Tagbor, MBChB, DrPH, editorial consultant, has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Rick M. Fairhurst, MD, PhD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Thomas E. Wellems, MD, PhD has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Darren B. Taichman, MD, PhD, Editor, PIER, has received grant support from Actelion Pharmaceuticals Ltd , and honoraria for continuing medical education grand rounds and lectures given.


The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2010 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.